Botulinum toxin type A therapy in a patient with cervical dystonia and amyotrophic lateral sclerosis [7]

Movement Disorders

Volumn 22, Issue 2, 2007, Pages 289-

  Singer, Carlos ^a   Papapetropaulos, Spiridon ^a   Ayyar, D Ram ^a   Verma, Ashok ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; CLONAZEPAM; OXAZEPAM; TRIHEXYPHENIDYL;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; CASE REPORT; CERVICAL SPINAL CORD INJURY; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE REDUCTION; DYSTONIA; ELECTROMYOGRAPHY; FEMALE; HUMAN; HYPERSALIVATION; LETTER; MUSCLE STRENGTH; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; NEUROMUSCULAR AGENTS; TORTICOLLIS;

EID: 33847704541     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21213     Document Type: Letter

References (7)

1. Costa J, Espirito-Santo C, Borges A, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 2005;CD003633.
2. Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry 1997;62:198.
3. Mezaki T, Kaji R, Kohara N, Kimura J. Development of general weakness in a patient with amyotrophic lateral sclerosis after focal botulinum toxin injection. Neurology 1996;46:845-846.
4. Emmerson J. Botulinum toxin for spasmodic torticollis in a patient with myasthenia gravis. Mov Disord 1994;9:367.
5. Goncalves MR, Barbosa ER, Zambon AA, Marchiori PE. Treatment of cervical dystonia with botulinum toxin in a patient with myasthenia gravis. Arq Neuropsiquiatr 1999;57:683-685.
6. Fasano A, Bentivoglio AR, Ialongo T, Soleti F, Evoli A. Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia. Neurology 2005;64:2155-2156.
7. Giess R, Naumann M, Werner E, et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000;69:121-123.